Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23910066 | 0.81 | ALDH1A1 (0.54) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL23910092 | 0.81 | ALDH1A1 (0.51) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL21071846 | 0.81 | LMNA (0.51) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL23910013 | 0.80 | ALDH1A1 (0.52) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL21071766 | 0.80 | ALDH1A1 (0.52) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL21071497 | 0.79 | KDM4E (0.46) | LMNAGAAALDH1A1MAPTMEN1 | |
| SCHEMBL23909943 | 0.79 | ALDH1A1 (0.51) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL23910106 | 0.77 | LMNA (0.53) | LMNAGAAALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL13713024 | 0.75 | MAPT (0.48) | LMNAGAASMN1; SMN2MAPTMEN1 | |
| SCHEMBL20283629 | 0.74 | BCHE (0.61) | LMNAGAAALDH1A1SMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | LMNA 2967/4885GAA 521/4885ALDH1A1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.